YouTube video by HealthTree Foundation for Multiple Myeloma Iberdomide Combos Post-ASCT in Myeloma: Eliminating Residual Disease (COMMANDER) |Dr. Costa | #ASH24

Reaching MRD negativity is the goal of #myeloma treatment. The CoMMander trial used Iberdomide to achieve this in Post-ASCT patients who had residual disease after 100 days. @healthtreeorg.bsky.social #MMSM #ASH24 m.youtube.com/watch?v=MiWM...

Congratulations to the lucky winners of our raffle at #HealthTree Booth 19! Thank you all for stopping by and participating in #ASH24
Xiuli Wang, Vishal Sahu, Melinda Atnip & Eli Soyfer

@JayHydren, HealthTree's Director of Clinical Research, presenting the abstract on Patient-Centered Care in Hematology: How Side Effect Severity Influences Decision-Making Autonomy in RRMM at #ASH24

📢 Breaking news from #ASH24! Daratumumab vs. active monitoring in smoldering myeloma shows:
✅ Significantly delayed disease progression
✅ Improved survival
✅ Under FDA review for high-risk SMM

This could transform early myeloma treatment from "watch & wait" to active intervention! #MyelomaResearch

🚨Breakthrough at #ASH24: Dr. Rau presents game-changing results for pediatric ALL treatment! After 20 years of plateau, adding blinatumomab to standard therapy showed such remarkable improvement in SR B-ALL that trial randomization was stopped early. A historic moment for the ALL community!

#Lymphoma doctors are tiredlessly trying to improve the first line treatment for LBCL. By adding new targeted agents to R-CHOP, more patients achieve faster and deeper responses. Will we ever see a better option without chemo? The fight continues!💪 #ASH24 #lymsm #chemofree

Early but promsing data just presented by @RaabMarc at #ASH24 on using bispecific antibodies in first line! A 100% of patients tested who received teclistamab with Dara + Len or Dara + Len + Bortezomib were MRD negative after just 3 cycles of induction! #mmsm #myeloma

Here we go! So great to see our amazing HealthTree Coaches Michael Riotto, Valarie Traynham and Tony Newberne crushing it at the #ASHRunWalk! 🏃‍♀️🏃‍♂️🔥 Inspiring energy and dedication! #ash24

Great discussion at #ASH24 during the Health Equity Studio session on achieving equity and inclusion in clinical trial enrollment. Important conversations on ensuring diverse patient representation for better outcomes. #HealthEquity #ClinicalTrials #ASH2024 #HealthTree

There are great expectations for Menin Inhibitors to be the new therapy class that finally moves the needle in acute #leukemia. With the first one just approved in the US, it’s great to hear how fast things are moving! With upcoming phase 2/3 trials and combinations!#leusm #ASH24

The BMS Health Equity Talk at #ASH24 sparked important conversations about advancing health equity and ensuring access to care for all. Grateful for the insights shared and the ongoing efforts to create a more inclusive healthcare system.
#HealthEquity

Learn how to build a free registry at HealthTree’s Non-Profit Booth 19. Also, enter to win a Stanley water bottle or Cotopaxi bag!
#ASH24 #HealthTree #PatientAdvocacy #InnovationThatSavesLives
#ASHMeeting #Hematology #BloodCancer #MedicalResearch #CancerCare #ASH2024 #MMsm #HealthTree #myeloma

Standing room and some of us sitting on the floor to hear the latest on #CARTs for large B-cell lymphoma. Lots of excitement about how newer cell therapies can be delivered faster to patients with #lymphoma. Great start to #ASH24!!

#HealthTree #bloodcancer #lymsm #hematology

A big thank you to our esteemed faculty—Drs. Guillermo Garcia-Manero, María Díez Campelo, and Valeria Santini—and our partner @healthtreeorg.bsky.social for making the Shifting to Higher Standards in #MDS symposium at #ASH24 a success!
#Oncsky #Medsky

Get the Best Care for Your Chronic Lymphocytic Leukemia - CLL Society Addressing the unmet needs of the Chronic Lymphocytic Leukemia (CLL) community, our goal is to provide recent and relevant information for CLL patients.

During #ASH24, we sat down with our incredible partners from the CllSociety.org and @healthtreeorg.bsky.social to discuss how our collaborations enhance medical education, support healthcare providers, and improve patient outcomes in #CLL, #Myelofibrosis, and #MDS. 🎥✨

If you're a lymphoma or leukemia doctor, we'd love to hear from you! There's still time to schedule your interview at #ASH24 with our HealthTree News team. Your groundbreaking work could make a real difference for patients! Book your spot here: buff.ly/41jQSwm
#HealthTree #lymsm #leusm

Live from #ASH24, highlighting presentations by Guillermo Garcia-Manero, MD, María Díez Campelo, MD, PhD, and Valeria Santini, MD, on the latest #MDS updates. Thrilled to partner with @peerview.bsky.social to share these insightful sessions!